Syntex (u.s.a.) Inc.

Roche Palo Alto LLC

Anthony Prince

David Bruce Repke

Hans Maag

Lawrence Emerson Fisher

Ralph New Harris, Iii

Russell Stephen Stabler

Charles Alois Dvorak

Keena Lynn Green

Denis John Kertesz

John O Gardner

Norman H Dyson

Keshab Sarma

Joseph Armstrong Martin

Terrence Joseph Connolly

Jack Ackrell

Otto Halpern

This invention relates to compounds which are generally muscarinic M2/M3 receptor antagonists and which are represented by Formula I: wherein X, Y, and Z are O, S or NR, and the other substituents are as defined in the specification; and prodrugs, individual isomers, racemic or non-racemic mixtures of isomers, and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use as therapeutic agents.

Heterocyclylakylamines as muscarinic receptor antagonists

Heterocyclylalkylamines as muscarinic receptor antagonists

The present invention relates to the hemisulfate salt of 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine (Ia) with improved stability and physical properties which facilitate manufacturing, handling and formulating I and polymorphic crystalline forms thereof.

Anhydrous crystalline 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine hemisulfate as useful as an antiviral agent

This invention provides an improved process for the preparation of compounds of formula (I): ##STR1## wherein: n is 0, 1 or 2;

Process for preparing 1,3-dioxolane derivatives

This invention relates to a novel method for the preparation of 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-acetic acid and the novel intermediate 6,11-dihydrodibenzo-[b.e.]-thiepin-11-one-3-carboxaldehyde used in the preparation thereof.

6,11-Dihydrodibenzo-[b.e.]-thiepin-11-one-3-carboxaldehyde

Growing community of inventors

Los Altos, CA, United States of America

Anthony Prince